Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

A Marker Predicting Distant Metastasis (Spread) in Breast Cancer: IL-6

A Marker Predicting Distant Metastasis (Spread) in Breast Cancer: IL-6

Researchers found that the inflammatory cytokine (a biological marker of inflammation ) known as interleukin-6(IL-6) may, in patients treated for stage 2 and 3 HER2-negative breast cancer, help predict whether their cancer will recur with metastasis by serving as a biomarker for that recurrence.

What is IL-6?

Interleukin-6 (IL-6) is a protein made by leukocytes (white blood cells) and other cells in the body, and is a type of cytokine.

Interleukin-6 is mainly made by certain T lymphocytes. When secreted, it causes B lymphocytes to produce more antibodies, and also causes fever by affecting the regions of the brain that control body temperature.

Laboratory-made, or synthetic, interleukin-6 is used as a biological response modifier to strengthen the immune system in cancer treatment. Conversely, drugs that block IL-6 are being tested in some diseases to calm an abnormal immune response, one of which is Covid-19. In conclusion, interleukin-6 is a type of cytokine with key roles in the functioning of the immune system. However, the roles of IL-6 are not limited to this; it has important functions in many metabolic and physiological processes in the body.

IL-6 in predicting breast cancer metastasis

Estrogen receptor (ER)-positive breast cancer was studied in a case-control study of 498 women treated with surgery and adjuvant chemotherapy, as well as endocrine (hormone-suppressing) therapies. Women with higher serum IL-6 levels at diagnosis, compared with women with lower levels, had a significantly higher risk of disease recurrence according to the findings.

At the ASCO 2021 Annual Meeting, these results were described as follows: "In high-risk stage II-III breast cancer, this provides level 1B (strong) evidence that higher levels at diagnosis of the cytokine IL-6 are associated with a significantly higher risk of distant recurrence despite optimal adjuvant systemic therapy".

Dr. Sparano, who presented the study, also stated that their findings needed to be confirmed in a larger study.

"Once confirmed, I think the other important issue is trying to understand what the best IL-6 cut-off point is for identifying high risk" he said.

A new target

Sparano and colleagues stated that knowledge is growing that systemic inflammation is a contributing factor in cancer progression and disease recurrence.

If further studies confirm that higher IL-6 levels are prognostic (predictive of disease course) for worse outcomes, it may be possible to use cytokine levels as a biomarker to predict therapies targeting the IL-6/Janus kinase/STAT3 pathway.

"There are ongoing clinical trials testing IL-6 antibodies in combination chemotherapy, and this could be a rational biomarker to identify which patients would be more likely to benefit from this approach" he said.

Sources

Joseph A. Sparano, et al. American Society of Clinical Oncology 2021 Annual Meeting. (Abstract 520)

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

A Marker Predicting Distant Metastasis (Spread) in Breast Cancer: IL-6

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy